

Sensorion Announces its Participation in the 60th Annual Inner Ear Biology Workshop

Montpellier, September 4, 2025, 7.30 am CET – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in the 60th annual Workshop on Inner Ear Biology, held on September 13-16, 2025, Tübingen, Germany.

On that occasion, Géraldine Honnet, M.D. Sensorion's Chief Medical Officer, will make the following oral presentation on Saturday, September 13, 2025, from 1.10 pm to 1.30 pm CET, followed by a round table:

"SENS-501 Gene Therapy in Young Children with Severe to Profound Hearing Loss Due to Otoferlin Mutations"

During the event, Anne-Gabrielle Harrus, Ph.D., Preclinical Scientist II, will present the following poster on Monday, September 15, 2025, from 1 pm to 2.30 pm CET:

"Safety and efficacy of GJB2-GT, An Adeno-Associated Vector-Based Gene Therapy Treatment Candidate for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A)" Poster #P70.

This poster will be available on Sensorion's website after the poster session.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Contacts

Investor Relations

Noémie Djokovic, Investor Relations and
Communication Associate

ir.contact@sensorion-pharma.com

Press Relations

Ulysse Communication

Bruno Arabian / 00 33(0)6 87 88 47 26

barabian@ulyссе-communication.com

Nicolas Entz / 00 33 (0)6 33 67 31 54

nentz@ulyссе-communication.com

Label: **SENSORION**

ISIN: **FR0012596468**

Mnemonic: **ALSEN**



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.